Urology
Volume 54, Issue 6 , Pages 960-963 , December 1999

Quercetin in men with category III chronic prostatitis: a preliminary prospective, double-blind, placebo-controlled trial

  • Daniel A Shoskes

      Affiliations

    • Institute for Male Urology, Encino, California, USA
    • Division of Urology, Harbor-UCLA Medical Center, University of California, Los Angeles, School of Medicine, Torrance, California, USA
    • D. A. Shoskes and J. Rajfer own stock in companies that will benefit from sales of the supplements reported in this study.
    • Corresponding Author InformationReprint requests: Daniel A. Shoskes, M.D., Division of Urology, Harbor-UCLA Medical Center, Box 5, 1000 West Carson Street, Torrance, CA 90502
    • ,
  • Scott I Zeitlin

      Affiliations

    • Institute for Male Urology, Encino, California, USA
    • Division of Urology, Harbor-UCLA Medical Center, University of California, Los Angeles, School of Medicine, Torrance, California, USA
    • ,
  • Asha Shahed

      Affiliations

    • Division of Urology, Harbor-UCLA Medical Center, University of California, Los Angeles, School of Medicine, Torrance, California, USA
    • ,
  • Jacob Rajfer

      Affiliations

    • Institute for Male Urology, Encino, California, USA
    • Division of Urology, Harbor-UCLA Medical Center, University of California, Los Angeles, School of Medicine, Torrance, California, USA

Received 2 August 1999 ,Revised 19 August 1999 ,Accepted 19 August 1999.

References 

  1. Nickel JC. Prostatitis (myths and realities). Urology. 1998;51:362–366
  2. Moon TD. Questionnaire survey of urologists and primary care physicians’ diagnostic and treatment practices for prostatitis. Urology. 1997;50:543–547
  3. Shoskes DA. Effect of the bioflavonoids quercetin and curcumin on ischemic renal injury (a new class of renoprotective agents). Transplantation. 1998;66:147–152
  4. Shoskes DA. Use of the bioflavonoid quercetin in patients with longstanding chronic prostatitis. J Am Neutraceut Assoc. 1999;2:18–21
  5. Chronic Prostatitis Collaborative Research Network Litwin MS, McNaughton-Collins M, Fowler FJ, et al.  The National Institutes of Health chronic prostatitis symptom index: development and validation of a new outcome measure. J Urol. 1999;162:369–375
  6. Tanner MA, Shoskes D, Shahed A, et al.  Prevalence of corynebacterial 16S rRNA sequences in patients with bacterial and “nonbacterial” prostatitis. J Clin Microbiol. 1999;37:1863–1870
  7. Kaplan SA, Santarosa RP, D’Alisera PM, et al.  Pseudodyssynergia (contraction of the external sphincter during voiding) misdiagnosed as chronic nonbacterial prostatitis and the role of biofeedback as a therapeutic option. J Urol. 1997;157:2234–2237
  8. Neal DE, Moon TD. Use of terazosin in prostatodynia and validation of a symptom score questionnaire. Urology. 1994;43:460–465
  9. Barbalias GA, Nikiforidis G, Liatsikos EN. Alpha-blockers for the treatment of chronic prostatitis in combination with antibiotics. J Urol. 1998;159:883–887
  10. Satyanarayana K, Shoskes DA. A molecular injury-response model for the understanding of chronic disease. Mol Med Today. 1997;3:331–334
  11. de Vries JH, Janssen PL, Hollman PC, et al.  Consumption of quercetin and kaempferol in free-living subjects eating a variety of diets. Cancer Lett. 1997;114:141–144
  12. Haenen GR, Paquay JB, Korthouwer RE, et al.  Peroxynitrite scavenging by flavonoids. Biochem Biophys Res Commun. 1997;236:591–593
  13. Chang WS, Lee YJ, Lu FJ, et al.  Inhibitory effects of flavonoids on xanthine oxidase. Anticancer Res. 1993;13:2165–2170
  14. Middleton E, Anne S. Quercetin inhibits lipopolysaccharide-induced expression of endothelial cell intracellular adhesion molecule-1. Int Arch Allergy Immunol. 1995;107:435–436
  15. Sato M, Miyazaki T, Kambe F, et al.  Quercetin, a bioflavonoid, inhibits the induction of interleukin 8 and monocyte chemoattractant protein-1 expression by tumor necrosis factor-alpha in cultured human synovial cells. J Rheumatol. 1997;24:1680–1684
  16. Mookerjee BK, Lee TP, Lippes HA, et al.  Some effects of flavonoids on lymphocyte proliferative responses. J Immunopharmacol. 1986;8:371–392
  17. Lee SC, Kuan CY, Yang CC, et al.  Bioflavonoids commonly and potently induce tyrosine dephosphorylation/inactivation of oncogenic proline-directed protein kinase FA in human prostate carcinoma cells. Anticancer Res. 1998;18:1117–1121
  18. Hilliard JJ, Krause HM, Bernstein JI, et al.  A comparison of active site binding of 4-quinolones and novel flavone gyrase inhibitors to DNA gyrase. Adv Exp Med Biol. 1995;390:59–69
  19. Aziz NH, Farag SE, Mousa LA, et al.  Comparative antibacterial and antifungal effects of some phenolic compounds. Microbios. 1998;93:43–54
  20. Hollman PC, de Vries JH, van Leeuwen SD, et al.  Absorption of dietary quercetin glycosides and quercetin in healthy ileostomy volunteers. Am J Clin Nutr. 1995;62:1276–1282
  21. Boulton DW, Walle UK, Walle T. Extensive binding of the bioflavonoid quercetin to human plasma proteins. J Pharm Pharmacol. 1998;50:243–249
  22. Bock U, Kolac C, Borchard G, et al.  Transport of proteolytic enzymes across Caco-2 cell monolayers. Pharm Res. 1998;15:1393–1400
  23. Canale D, Scaricabarozzi I, Giorgi P, et al.  Use of a novel non-steroidal anti-inflammatory drug, nimesulide, in the treatment of abacterial prostatovesiculitis. Andrologia. 1993;25:163–166
  24. Hellstrom WJ, Schmidt RA, Lue TF, et al.  Neuromuscular dysfunction in nonbacterial prostatitis. Urology. 1987;30:183–188
  25. Nickel JC, Sorenson R. Transurethral microwave thermotherapy of nonbacterial prostatitis and prostatodynia (initial experience). Urology. 1994;44:458–460
  26. Shoskes DA, Zeitlin SI. Use of prostatic massage in combination with antibiotics in the treatment of chronic prostatitis. Prostate Cancer Prostate Dis. 1999;2:159–162

PII: S0090-4295(99)00358-1

Urology
Volume 54, Issue 6 , Pages 960-963 , December 1999

Article Tools

* Image Usage & Resolution